Tezepelumab & OITEfficacy of Tezepelumab in Peanut Oral Immunotherapy

Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Code:

NCT07015996

Conditions

Peanut Allergy

Eligibility Criteria

Sex: All

Age: 12 - 55

Healthy Volunteers: Not accepted

Interventions

Tezepelumab

Peanut Oral Immunotherapy (OIT)

Placebo for Tezepelumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-26. This information was provided to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID) on 2026-06-26.